Does Nucleos(t)ide (NUC) Analogs Therapy in Hepatitis B Impact the Incidence of Liver Cancer?
详细信息 查看全文
- 作者：Walid S. Ayoub ; Paul Martin ; Pietro Lampertico
- 关键词：Hepatitis B ; Liver cancer ; Hepatocellular carcinoma ; Nucleos(t)ides ; Tenofovir ; Entecavir ; Lamivudine
- 刊名：Current Hepatitis Reports
- 出版年：2015
- 出版时间：December 2015
- 年：2015
- 卷：14
- 期：4
- 页码：279-283
- 全文大小：245 KB
- 参考文献：1.Ferlay J, Soerjomataram II, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer J Int du Cancer 2014.<br>2.Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet] Lyon, France: international agency for research on cancer; 2013 Available from: http://鈥媑lobocan.鈥媔arc.鈥媐r , accessed on 09/17/2014.<br>3.Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020鈥?.PubMedCentral CrossRef PubMed <br>4.Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009;101:1348鈥?5.CrossRef PubMed <br>5.Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521鈥?1.CrossRef PubMed <br>6.Marcellin P, Buti M, Krastev Z, et al. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. J Hepatol. 2014;61:1228鈥?7.CrossRef PubMed <br>7.Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661鈥?.CrossRef PubMed <br>8.Gish RG, Chang TT, Lai CL, et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat. 2010;17:16鈥?2.CrossRef PubMed <br>9.Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2011;34:1145鈥?8.CrossRef PubMed <br>10.Vlachogiannakos J, Papatheodoridis G. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. World J Gastroenterology: WJG. 2013;19:8822鈥?0.PubMedCentral CrossRef PubMed <br>11.Kao JH, Liu CJ, Jow GM, Chen PJ, Chen DS, Chen BF. Fine mapping of hepatitis B virus pre-S deletion and its association with hepatocellular carcinoma. Liver Int: Off J Int Assoc Study Liver. 2012;32:1373鈥?1.CrossRef <br>12.Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142:1140鈥? e3. quiz e13-4.CrossRef PubMed <br>13.鈥?/div>Triolo M, Della Corte C, Colombo M. Impact of HBV therapy on the incidence of hepatocellular carcinoma. Liver Int: Off J Int Assoc Study Liver. 2014;34 Suppl 1:139鈥?5. The bulleted references provide an updated analysis of the literature demonstrating the chemopreventive properties of NA therapy. The references demonstrate the impact of hepatitis B therapy on the risk of development of HCC with oral agents with low and high genetic barriers to resistance. CrossRef <br>14.Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335鈥?2.CrossRef PubMed <br>15.Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2008;28:1067鈥?7.CrossRef PubMed <br>16.鈥?/div>Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53:348鈥?6. The bulleted references provide an updated analysis of the literature demonstrating the chemopreventive properties of NA therapy. The references demonstrate the impact of hepatitis B therapy on the risk of development of HCC with oral agents with low and high genetic barriers to resistance. CrossRef PubMed <br>17.Jeng WJ, Sheen IS, Chen YC, et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology. 2013;58:1888鈥?6.CrossRef PubMed <br>18.鈥⑩€?/div>Liaw YF. Impact of therapy on the long-term outcome of chronic hepatitis B. Clinics Liver Dis. 2013;17:413鈥?3. The bulleted references provide an updated analysis of the literature demonstrating the chemopreventive properties of NA therapy. The references demonstrate the impact of hepatitis B therapy on the risk of development of HCC with oral agents with low and high genetic barriers to resistance. CrossRef <br>19.Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58:98鈥?07.CrossRef PubMed <br>20.Wong GL, Chan HL, Mak CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58:1537鈥?7.CrossRef PubMed <br>21.Kumada T, Toyoda H, Tada T, et al. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol. 2013;58:427鈥?3.CrossRef PubMed <br>22.Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886鈥?3.CrossRef PubMed <br>23.鈥⑩€?/div>Coffin CS, Rezaeeaval M, Pang JX, et al. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy. Aliment Pharmacol Ther. 2014;40:1262鈥?. The bulleted references provide an updated analysis of the literature demonstrating the chemopreventive properties of NA therapy. The references demonstrate the impact of hepatitis B therapy on the risk of development of HCC with oral agents with low and high genetic barriers to resistance. CrossRef PubMed <br>24.Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468鈥?5.CrossRef PubMed <br>25.Kim W, Berg T, Loomba R, et al. Long term tenofovir disoproxil fumarate (TDF) therapy and the risk of hepatocellular carcinoma. J Hepatol. 2013;58:S19.CrossRef <br>26.Papatheodoridis GV, Dalekos GN, Yurdaydin C, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol 2014.<br>27.鈥⑩€?/div>Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015;62:956鈥?7. The bulleted references provide an updated analysis of the literature demonstrating the chemopreventive properties of NA therapy. The references demonstrate the impact of hepatitis B therapy on the risk of development of HCC with oral agents with low and high genetic barriers to resistance. CrossRef PubMed <br>28.Huang G, Lau WY, Wang ZG, et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. Ann Surg. 2015;261:56鈥?6.CrossRef PubMed <br>29.Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA: J Am Med Assoc. 2012;308:1906鈥?4.CrossRef <br>
- 作者单位：Walid S. Ayoub (1) <br> Paul Martin (2) <br> Pietro Lampertico (3) <br><br>1. Department of Digestive and Liver Diseases, Cedars Sinai Medical Center, 8900 Beverly Blvd, Suite 250, Los Angeles, CA, 90048, USA <br> 2. University Miami School of Medicine, 1500 NW 12th Ave, Suite 1101, Miami, FL, 33136-1052, USA <br> 3. Gastroenterology and Hepatology Division, Fondazione IRCCS Ca鈥?Granda Ospedale Maggiore Policlinico, Universit脿 di Milano, Via Francesco Sforza 35, 20122, Milan, Italy <br>
- 刊物主题：Hepatology;
- 出版者：Springer US
- ISSN：1541-0706
文摘
Hepatocellular carcinoma (HCC) is a major source of mortality. It is the second most common cause of death worldwide, the fifth most common cancer in men, and ninth in women. It is estimated that 782,000 cases are diagnosed annually, of which half occurs on China [1]. It is more prevalent in Eastern and South-Eastern Asia and less prevalent in the USA and Northern Europe [2]. It carries a high burden on society and significantly impairs quality of life. It is estimated that up to 746,000 deaths occurs annually from hepatocellular carcinoma with approximately half of the death associated with hepatitis B [2]. Fortunately, an increasing body of evidence confirms the efficacy of HBV vaccination and antiviral therapy in reducing the incidence of HCC. In this review, we address treatment of hepatitis B and its impact on development of HCC. Keywords Hepatitis B Liver cancer Hepatocellular carcinoma Nucleos(t)ides Tenofovir Entecavir Lamivudine